MannKind Corporation presented new clinical and real-world data at ADA 2026 supporting the safety and effectiveness of Afrezza, its inhaled insulin, recently approved for children aged 6 and older with type 1 and type 2 diabetes. Studies showed Afrezza offers comparable glycemic control to rapid-acting insulin analogs with added benefits like improved treatment satisfaction in youth and fewer hypoglycemic events in gestational diabetes. Exploratory data also suggest favorable use with automated insulin delivery systems. These findings reinforce Afrezza as a patient-friendly alternative for diabetes management across various populations, with ongoing research to expand its clinical applications.
At B2Gold Corp's 2026 Annual General and Special Meeting, shareholders voted on key company matters with 63.06% turnout. All ten nominated directors were re-elected with strong support, and resolutions to appoint PricewaterhouseCoopers LLP as auditor...
Jim Rickards highlights a tiny $2 stock holding exclusive rights to a massive $2.7 trillion mineral deposit in the US, containing gold, copper, silver, and critical metals vital for technology and defense. The project has been stalled by environmenta...
Aurion Resources Ltd. shareholders overwhelmingly approved a plan for Agnico Eagle Mines Limited to acquire all outstanding Aurion shares at C$2.60 each. The approval was secured at a special meeting, with over 99% voting in favor. The transaction no...
Anika Therapeutics granted 3,360 restricted stock units (RSUs) to a newly hired non-executive employee on June 1, 2026. This grant was made under the company's 2021 Inducement Plan as a material inducement for accepting employment, in compliance with...
Boralex Inc. has received final approval from the Superior Court of Québec for its arrangement with BIF Thunder Holdings Inc., jointly owned by Brookfield Infrastructure Fund V and Caisse de dépôt et placement du Québec. This approval follows shareho...
